|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
One out of three adults in the United States are obese but the most optimal approach to antibiotic dosing in this population remains controversial. For antibiotics that are weight-based, selection of the best body size descriptor is often unclear when managing a patient that is obese. Likewise, concerns exist whether a “once-size-fits-all” dosing regimen is sufficient for a patient that is obese. This webinar will provide a historical and contemporary perspective on the definition of obesity and body size description. The pharmacologic approach to initial and maintenance dose selection will be reviewed to harmonize current divergent approaches. Patient case and drug case scenarios will illustrate pragmatic methods of informing antibiotic dose selection in obesity.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Review the epidemiology and definition of obesity.
- Outline the rationale for optimal dose selection.
- Link pharmacokinetic parameters with the choice of initial and maintenance dose selection.
- Illustrate the similarity and differences in body size scalars for drug dosing across age.
- Discuss the rationale for alternate approaches to dose selection.
- Review specific antimicrobial dosing approaches to demonstrate potential areas of improvement.
Manjunath (Amit) P. Pai, PharmD, FCP
Associate Professor of Clinical Pharmacy
Deputy Director, Pharmacokinetics Core
College of Pharmacy, University of Michigan
Release Date: 09-26-2019
Expiration Date: 09-26-2022
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-498-H01-P has been assigned to this home study knowledge-based activity (initial release date 9-26-2019). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Pai is a consultant for Paratek Pharmaceuticals.
This activity is provided by ProCE, Inc. and SIDP.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
LIVE Webinar Attendance (Enter Event/Attendance Code provided during webinar to verify attendance)
|Date||9/26/2019 12:00:00 PM|